Pharma BD Deal Intelligence
BioSpace reported Lilly would pay up to $380M ($180M upfront plus up to $200M in regulatory and commercial milestones) for Alnara, framing it as a strategic…
Nature Biotechnology covered the Alnara acquisition as a meaningful entry by Lilly into the pancreatic enzyme replacement market, noting the differentiated…
GEN reported Lilly took a $122.6M impairment in 2012 after FDA issued a Complete Response Letter on liprotamase in 2011, then divested the asset to Anthera in…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Lilly to acquire Alnara for $180M upfront + up to $200M development/regulatory milestones. Adds Phase 3-ready protein therapeutic for pancreatic insufficiency.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Alnara Pharmaceuticals (this deal) | 2010 | $380M | 13 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2010 deals · Eli Lilly and Company deals · Gastroenterology deals